Literature DB >> 1516604

FARMAGUIDA: a databank for the analysis of the Italian drug market and drug utilization in general practice.

N Montanaro1, A Vaccheri, N Magrini, M Battilana.   

Abstract

FARMAGUIDA, a databank of drugs marketed in Italy (2,596 pharmaceutical substances corresponding to 10,448 products), permits analysis of the nature and value of the drugs prescribed. It contains coded pharmaceutical and administrative information, an original classification, as well as indicators of the therapeutic status of each drug. The FARMAGUIDA classification was built hierarchically according to a three-level pattern: the first level (42 categories) corresponds to major pharmacological groups; the second level (157 groups) gathers drugs having similar clinical indications and/or pharmacological actions; and the third level (246 subgroups) classifies drugs according to chemical structure and/or the mechanism of action. Drugs not falling into well-established pharmacotherapeutic criteria (e.g. neurotropics or liver protectants) are classified into separate subgroups. Two larger groupings were also formulated: THER (11 headings), a utilization-oriented arrangement in which each heading also contained the corresponding placebo-like drugs, and PHARM (14 headings), a rational pharmacological arrangement, in which all placebo-like drugs were relegated into a separate set. The following quality indicators were created: DOC, which defines five degrees of documentation of clinical efficacy according to major textbooks of pharmacology and therapeutics; CLASS, which groups DOC values for a more simple evaluation of prescription data; PREP, which distinguishes monocomponent preparations from fixed-dose combinations, and also provides coded information about the rationale for the combination; HOSP, which hallmarks drugs that should be reserved for in-patients, e.g. anti-pseudomonal antibiotics. The composition of the list of reimbursable drugs, the Italian National Formulary (NF; 5782 products in 1990) was analyzed according to the FARMAGUIDA classification and indicators.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1516604     DOI: 10.1007/bf00280125

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  1 in total

1.  Drug utilization studies: a tool for determining the effectiveness of drug use.

Authors:  J R Laporte; M Porta; D Capella
Journal:  Br J Clin Pharmacol       Date:  1983-09       Impact factor: 4.335

  1 in total
  5 in total

1.  Drug utilization in general practice: prescribing habits of National Formulary drugs by GPs of Emilia Romagna (Italy) in 1988 and 1989.

Authors:  N Montanaro; N Magrini; A Vaccheri; M Battilana
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Initial treatment of hypertension and adherence to therapy in general practice in Italy.

Authors:  Elisabetta Poluzzi; Petar Strahinja; Antonio Vargiu; Giacomo Chiabrando; Maria Chiara Silvani; Domenico Motola; Giulia Sangiorgi Cellini; Alberto Vaccheri; Fabrizio De Ponti; Nicola Montanaro
Journal:  Eur J Clin Pharmacol       Date:  2005-08-05       Impact factor: 2.953

3.  Individualized drug utilization statistics. Analysing a population's drug use from the perspective of individual users.

Authors:  J Hallas; A Nissen
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

4.  Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy.

Authors:  J Larsen; A Vaccheri; M Andersen; N Montanaro; U Bergman
Journal:  Br J Clin Pharmacol       Date:  2000-05       Impact factor: 4.335

5.  Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage.

Authors:  Elisabetta Poluzzi; Petar Strahinja; Alberto Vaccheri; Antonio Vargiu; Maria Chiara Silvani; Domenico Motola; Giulio Marchesini; Fabrizio De Ponti; Nicola Montanaro
Journal:  Br J Clin Pharmacol       Date:  2006-11-10       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.